舒血宁联合西药治疗瘀血阻络型急性脑梗塞随机平行对照研究

Blood Stasis in Acute Cerebral Infarction Randomized Controlled Study combined with Western Medicine Shuxuening

[目的]观察舒血宁联合西药治疗瘀血阻络型急性脑梗塞疗效。[方法]使用随机平行对照方法,将100例门诊及住院患者按病志号抽签法简单随机分为两组。溶栓治疗、抗凝、降纤、血液稀释、脑保护剂钙离子拮抗剂等治疗。对照组50例120mg川芎嗪+250m L 0.9g氯化钠,1次/d。治疗组50例20m L舒血宁+250m L 0.9g氯化钠,1次/d。连续治疗7d为1疗程。观测临床症状、全血黏度低切、全血黏度高切、血浆黏度、功能缺损评分、不良反应。连续治疗2疗程,判定疗效。[结果]治疗组痊愈30例,显效12例,有效4例,无效4例,总有效率92.00%。对照组痊愈21例,显效10例,有效7例,无效12例,总有效率76.00%。治疗组疗效优于对照组(P<0.05)。血液流变指标两组均有改善(P<0.05),治疗组改善优于对照组(P<0.05)。神经功能缺损评分两组均有改善(P<0.05),治疗组改善优于对照组(P<0.05)。[结论]舒血宁联合西药治疗瘀血阻络型急性脑梗塞疗效满意,无严重不良反应,值得推广。

[Objective] View Cha Shu Xue Ning combined with western medicine blood stasis effect of acute cerebral infarction.[Methods] randomized, parallel controlled method, 100 outpatients and inpatients by disease Zhi No. lottery method is simple and randomly divided into two groups. Thrombolytic therapy, anticoagulation, fibrinolytic, hemodilution, brain-protecting agent calcium antagonist therapy. The control group of 50 patients 120 mg TMP＋250m L 0.9g sodium chloride, 1 times/d. Treatment group of 50 patients 20 m L shuxuening ＋ 250 m L 0.9g sodium chloride, 1 times/d. 7d for a course of continuous treatment. Observation of clinical symptoms, blood viscosity at low shear, high shear whole blood viscosity, plasma viscosity, functional impairment score, adverse reactions. Continuous treatment of 2 courses, to determine efficacy. [Results] The cure 30 cases, 12 cases markedly effective in 4 cases, 4 cases, the total efficiency of 92.00%. Cured 21 cases in the control group, 10 cases markedly effective in 7 cases, 12 cases, the total efficiency of 76.00%. Treatment group than the control group（P〈0.05）. Hemorrheology indicators improved in both groups（P〈0.05）, the treatment group than the control group improved（P〈0.05）. Neurological function improved in both groups（P〈0.05）, the treatment group than the control group improved（P〈0.05）. [Conclusion] Shuxuening blood stasis combined with Western medicine treatment of acute cerebral infarction efficacy collaterals satisfaction, no side effects, worthy of promotion.